Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia

Condition(s) targeted: Cervical Dystonia

Intervention: botulinum toxin type A (Biological); botulinum toxin type A (Biological); Normal Saline (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Allergan

Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan

Overall contact:
Allergan Inc, Email: clinicaltrials@allergan.com

Study is to investigate the use of the TWSTRS scale in a cervical dystonia population treated with botulinum toxin type A, and placebo

Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study

Primary outcome: TWSTRS change from baseline

Secondary outcome:

Patient Global Assessment

Physician's global assessment scale

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of cervical dystonia

Exclusion Criteria:

- Current or previous botulinum toxin treatment of any type for any condition

Allergan Inc, Email: clinicaltrials@allergan.com

Zagreb, Croatia; Not yet recruiting

Prague, Czech Republic; Recruiting

Berlin, Germany; Not yet recruiting

Budapest, Hungary; Not yet recruiting

Mumbai, India; Not yet recruiting

Manila, Philippines; Not yet recruiting

Warsaw, Poland; Recruiting

Lisbon, Portugal; Not yet recruiting

Moscow, Russian Federation; Not yet recruiting

Belgrade, Serbia; Recruiting

Singapore, Singapore; Not yet recruiting

Banska Bystrica, Slovakia; Not yet recruiting

Johannesburg, South Africa; Not yet recruiting

Bern, Switzerland; Not yet recruiting

Tainan, Taiwan; Not yet recruiting

Bangkok, Thailand; Not yet recruiting

Bristol, United Kingdom; Recruiting

Winston-Salem, North Carolina, United States; Recruiting

Halifax, Nova Scotia, Canada; Recruiting

Starting date: December 2007
Ending date: January 2011
Last updated: July 1, 2008